| pubmed-article:9040751 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9040751 | lifeskim:mentions | umls-concept:C0038522 | lld:lifeskim |
| pubmed-article:9040751 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9040751 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
| pubmed-article:9040751 | lifeskim:mentions | umls-concept:C1517942 | lld:lifeskim |
| pubmed-article:9040751 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:9040751 | lifeskim:mentions | umls-concept:C1517569 | lld:lifeskim |
| pubmed-article:9040751 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:9040751 | pubmed:dateCreated | 1997-3-26 | lld:pubmed |
| pubmed-article:9040751 | pubmed:abstractText | We treated 22 patients with subacute sclerosing panencephalitis (SSPE) with intraventricular alpha-interferon (alpha-IFN) and oral inosiplex between 1986 and 1991. The follow-up for 56 to 108 months demonstrates a higher survival rate in these patients compared with those who did not receive alpha-IFN. However, eight of 11 patients whose condition improved after alpha-IFN treatment and five of five patients whose condition stabilized after alpha-IFN experienced neurologic deterioration 6 to 90 months after treatment; three of 11 and four of five died. The use of inosiplex did not influence the prognosis. Re-administration of the same regimen was not effective in one patient. Treatment-induced remissions in SSPE can be temporary, analogous to spontaneous remissions. Longer treatment with higher doses, or combinations of drugs, may be required. | lld:pubmed |
| pubmed-article:9040751 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9040751 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9040751 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9040751 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9040751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9040751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9040751 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9040751 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9040751 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:9040751 | pubmed:issn | 0028-3878 | lld:pubmed |
| pubmed-article:9040751 | pubmed:author | pubmed-author:KöseGG | lld:pubmed |
| pubmed-article:9040751 | pubmed:author | pubmed-author:AnlarBB | lld:pubmed |
| pubmed-article:9040751 | pubmed:author | pubmed-author:YalazKK | lld:pubmed |
| pubmed-article:9040751 | pubmed:author | pubmed-author:OktemFF | lld:pubmed |
| pubmed-article:9040751 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9040751 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:9040751 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9040751 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9040751 | pubmed:pagination | 526-8 | lld:pubmed |
| pubmed-article:9040751 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9040751 | pubmed:meshHeading | pubmed-meshheading:9040751-... | lld:pubmed |
| pubmed-article:9040751 | pubmed:meshHeading | pubmed-meshheading:9040751-... | lld:pubmed |
| pubmed-article:9040751 | pubmed:meshHeading | pubmed-meshheading:9040751-... | lld:pubmed |
| pubmed-article:9040751 | pubmed:meshHeading | pubmed-meshheading:9040751-... | lld:pubmed |
| pubmed-article:9040751 | pubmed:meshHeading | pubmed-meshheading:9040751-... | lld:pubmed |
| pubmed-article:9040751 | pubmed:meshHeading | pubmed-meshheading:9040751-... | lld:pubmed |
| pubmed-article:9040751 | pubmed:meshHeading | pubmed-meshheading:9040751-... | lld:pubmed |
| pubmed-article:9040751 | pubmed:meshHeading | pubmed-meshheading:9040751-... | lld:pubmed |
| pubmed-article:9040751 | pubmed:meshHeading | pubmed-meshheading:9040751-... | lld:pubmed |
| pubmed-article:9040751 | pubmed:meshHeading | pubmed-meshheading:9040751-... | lld:pubmed |
| pubmed-article:9040751 | pubmed:meshHeading | pubmed-meshheading:9040751-... | lld:pubmed |
| pubmed-article:9040751 | pubmed:meshHeading | pubmed-meshheading:9040751-... | lld:pubmed |
| pubmed-article:9040751 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9040751 | pubmed:articleTitle | Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon. | lld:pubmed |
| pubmed-article:9040751 | pubmed:affiliation | Department of Pediatric Neurology, Hacettepe University, Ankara, Turkey. | lld:pubmed |
| pubmed-article:9040751 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9040751 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9040751 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9040751 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9040751 | lld:pubmed |
